TIZIANA LIFE SCIENCES LTD (TLSA) Stock News

NASDAQ:TLSA - Nasdaq - BMG889121031 - Common Stock - Currency: USD

1.48 +0.01 (+0.68%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TLSA Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: ELVN HCTI SNES NCNA ...

12 Health Care Stocks Moving In Friday's Intraday Session

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Bio International Convention

a month ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Bio International Convention

a month ago - By: Benzinga - Mentions: PRE CPHI HCTI NCNA ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: MarketBeat - Mentions: UBER TSLA

Uber Stock Ready to Ride Higher on Waymo Partnership

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

2 months ago - By: Tiziana Life Sciences Ltd.

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Purchase of Shares by Chairman

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

2 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

3 months ago - By: Yahoo Finance - Mentions: PHH ATPC MNPR AGL ...

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

3 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

4 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

5 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

6 months ago - By: Tiziana Life Sciences Ltd.

Tiziana Life Sciences not to engage in capital raising activities for the immediate future